Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, U.S.A.
Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, TX, U.S.A.
Anticancer Res. 2021 Dec;41(12):5953-5958. doi: 10.21873/anticanres.15414.
BACKGROUND/AIM: Knockdown of human copper transporter 1 has been associated with reduction in copper uptake and suppression of prostate cancer cell proliferation and tumor growth. This study evaluated the effects of steroid-based compounds on copper uptake and proliferation of prostate cancer cells based on their anticancer activity and previous docking analysis of steroid-based copper transporter 1 inhibitors.
We synthesized several new steroid-based compounds and used Cu uptake assay and copper quantification assay with inductively coupled plasma mass spectrometry to study their effects on the cellular copper uptake by prostate cancer cells. Additionally, we used CCK-8 cell proliferation assay to study their effects on the proliferation of prostate cancer cells.
Significant reduction in cellular copper uptake was observed in the prostate cancer cells treated with these new steroid-based compounds. Moreover, proliferation of prostate cancer cells was suppressed by treatment with the steroid-based compound , which had the strongest copper uptake inhibition activity.
Reduction in copper uptake and inhibition of cell proliferation were demonstrated in prostate cancer cells treated with the new steroid-based compounds synthesized in this study. Steroid-based copper transporter 1 inhibitors may become novel anticancer drugs for targeted anti-copper therapy of prostate cancer and other copper hypermetabolic cancers.
背景/目的:敲低人铜转运蛋白 1 已被证明与减少铜摄取以及抑制前列腺癌细胞增殖和肿瘤生长有关。本研究基于抗癌活性和先前对基于类固醇的铜转运蛋白 1 抑制剂的对接分析,评估了基于类固醇的化合物对前列腺癌细胞铜摄取和增殖的影响。
我们合成了几种新的基于类固醇的化合物,并使用 Cu 摄取测定和电感耦合等离子体质谱法的铜定量测定来研究它们对前列腺癌细胞中细胞内铜摄取的影响。此外,我们使用 CCK-8 细胞增殖测定来研究它们对前列腺癌细胞增殖的影响。
用这些新的基于类固醇的化合物处理前列腺癌细胞后,观察到细胞内铜摄取显著减少。此外,具有最强铜摄取抑制活性的基于类固醇的化合物处理抑制了前列腺癌细胞的增殖。
本研究合成的新型基于类固醇的化合物处理前列腺癌细胞后,显示出铜摄取减少和细胞增殖抑制。基于类固醇的铜转运蛋白 1 抑制剂可能成为针对前列腺癌和其他铜代谢过度癌症的靶向抗铜治疗的新型抗癌药物。